158 related articles for article (PubMed ID: 1544844)
1. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
Adams GE; Stratford IJ; Edwards HS; Bremner JC; Cole S
Int J Radiat Oncol Biol Phys; 1992; 22(4):717-20. PubMed ID: 1544844
[TBL] [Abstract][Full Text] [Related]
2. The experimental development of bioreductive drugs and their role in cancer therapy.
Workman P; Stratford IJ
Cancer Metastasis Rev; 1993 Jun; 12(2):73-82. PubMed ID: 8375022
[TBL] [Abstract][Full Text] [Related]
3. Bioreductive drugs in cancer therapy.
Stratford IJ
BJR Suppl; 1992; 24():128-36. PubMed ID: 1341908
[No Abstract] [Full Text] [Related]
4. Bioreductive therapies: an overview of drugs and their mechanisms of action.
Rauth AM; Melo T; Misra V
Int J Radiat Oncol Biol Phys; 1998 Nov; 42(4):755-62. PubMed ID: 9845091
[TBL] [Abstract][Full Text] [Related]
5. Bioreductive therapy.
Chaplin DJ
Int J Radiat Oncol Biol Phys; 1992; 22(4):685-7. PubMed ID: 1544837
[No Abstract] [Full Text] [Related]
6. Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo.
Minchinton AI; Lemmon MJ; Tracy M; Pollart DJ; Martinez AP; Tosto LM; Brown JM
Int J Radiat Oncol Biol Phys; 1992; 22(4):701-5. PubMed ID: 1544841
[TBL] [Abstract][Full Text] [Related]
7. Bioreductive agents: a clinical update.
Boyer MJ
Oncol Res; 1997; 9(6-7):391-5. PubMed ID: 9406245
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of interstitial photodynamic therapy by mitomycin C and EO9 in a mouse tumour model.
Baas P; Michielsen C; Oppelaar H; van Zandwijk N; Stewart FA
Int J Cancer; 1994 Mar; 56(6):880-5. PubMed ID: 8119776
[TBL] [Abstract][Full Text] [Related]
9. Bioreductive drugs and the selective induction of tumour hypoxia.
Bremner JC; Stratford IJ; Bowler J; Adams GE
Br J Cancer; 1990 May; 61(5):717-21. PubMed ID: 2110814
[TBL] [Abstract][Full Text] [Related]
10. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models.
Hendriks HR; Pizao PE; Berger DP; Kooistra KL; Bibby MC; Boven E; Dreef-van der Meulen HC; Henrar RE; Fiebig HH; Double JA
Eur J Cancer; 1993; 29A(6):897-906. PubMed ID: 8484984
[TBL] [Abstract][Full Text] [Related]
11. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity.
Plumb JA; Workman P
Int J Cancer; 1994 Jan; 56(1):134-9. PubMed ID: 8262670
[TBL] [Abstract][Full Text] [Related]
12. Targeting bioreductive drugs to tumours: is it necessary to manipulate blood flow?
Brown JM
Int J Radiat Biol; 1991; 60(1-2):231-6. PubMed ID: 1677976
[No Abstract] [Full Text] [Related]
13. Dual-function 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas.
Cole S; Stratford IJ; Adams GE; Fielden EM; Jenkins TC
Radiat Res; 1990 Oct; 124(1 Suppl):S38-43. PubMed ID: 2236508
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of bioreductive drugs in multicell spheroids.
Durand RE; Olive PL
Int J Radiat Oncol Biol Phys; 1992; 22(4):689-92. PubMed ID: 1544838
[TBL] [Abstract][Full Text] [Related]
15. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
16. Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs.
Edwards HS; Bremner JC; Stratford IJ
Int J Radiat Biol; 1991; 60(1-2):373-7. PubMed ID: 1677997
[No Abstract] [Full Text] [Related]
17. Interleukin-1 alpha-induced tumour pathophysiologies can be exploited with bioreductive alkylating agents.
Braunschweiger PG; Jones SA; Johnson CS; Furmanski P
Int J Radiat Biol; 1991; 60(1-2):369-72. PubMed ID: 1677996
[No Abstract] [Full Text] [Related]
18. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
Dorie MJ; Menke D; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
[TBL] [Abstract][Full Text] [Related]
19. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
[TBL] [Abstract][Full Text] [Related]
20. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
Brown JM; Lemmon MJ
Cancer Res; 1990 Dec; 50(24):7745-9. PubMed ID: 2253217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]